Ultime notizie per Smith Douglas Homes (NYSE:SDHC) Azioni

Smith Douglas Homes

Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.

Smith Douglas Homes Corp. Class A Common Stock

Smith Douglas Homes Corp

<p>Last week, <strong>Sotera Health Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) reported adjusted earnings per share of 14 cents, up from 13 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 12 cents</a>.</p>
<p>The sterilization solutions and lab testing and advisory services provider reported sales of $254.52 million, up 2.6% year over year (+4.4% at constant currency), beating the <a href="https://www.benzinga.com/pressreleases/25/05/g45131515/sotera-health-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">consensus of $245.79 million</a>.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a></strong></p>
<p>&#8220;We are pleased to report a solid start to the year with mid-single digit revenue growth and strong double-digit Adjusted EBITDA growth, on a constant currency basis,&#8221; said Chairman and CEO <strong>Michael B. Petras Jr</strong>. &#8220;We have consistently demonstrated the ability to sustain growth and navigate challenges through varying market conditions. Today, we are reaffirming our 2025 outlook as our team remains steadfast in our mission of Safeguarding Global Health.&#8221;</p>
<p><strong>Guidance: </strong>Sotera Health affirms fiscal 2025 adj. earnings per share of 70 cents-76 cents versus the consensus of 74 cents.</p>
<p>The company reaffirmed the sales outlook of $1.14 billion-$1.17 billion compared to the consensus of $1.13 billion.</p>
<p>Goldman Sachs writes, &#8220;Sotera Health is uniquely insulated from the current Tariff policy, given their largely service-based model and exemptions of their Cobalt-60 supply business under the USMCA.&#8221;</p>
<p>Analyst <strong>Matthew Sykes</strong> upgraded Sotera Health&#8217;s rating on Monday to Buy from Neutral and raised the <a href="https://www.benzinga.com/quote/SHC/analyst-ratings" target="_blank" rel="noreferrer noopener">price target to $17 from $14</a>, representing a 36% upside.</p>
<p>Sykes adds that given the uncertain macro backdrop, Sotera Health represents a defensive growth option within Goldman Sach&#8217;s coverage universe without a meaningful impact from tariffs exposure to academia and government exposure.</p>
<p>Sotera Health is in a strong position despite uncertainty around tariffs, thanks to its service-based business model in Sterigenics and Nelson Labs. Products from Nelson Cobalt are also exempt from tariffs under a U.S. trade rule. </p>
<p>The analyst added that there was significant legal uncertainty when Goldman Sachs began covering the stock with a Neutral rating in December 2024. However, the analyst now believes risk has decreased due to recent settlements.</p>
<p>&#8220;We believe SHC is an attractive way to gain exposure to the continued growth in the Medtech product innovation cycle. While potential litigation remains a risk, we believe the uncertainty has reduced following the recent IL settlement, and we expect this risk to lessen over time as they work through the process,&#8221; Skyes writes.</p>
<p><strong>SHC Price Action:</strong> Solear Health stock is up 5.33% at $13.04 at publication on Monday</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/05/45200539/alibabas-ant-group-eyes-hong-kong-ipo-for-ant-international-as-it-pushes-forward-with-fintech-growth" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s Fintech Arm Ant Group Eyes Hong Kong IPO For Ant International</a></strong></li>
</ul>
<p><em>Photo: bixstock via Shutterstock</em></p>


Analyst Color

Upgrades

Health Care

Price Target

Analyst Ratings

Movers

Sotera Health 'Is Uniquely Insulated From Potential Tariff Policy,' Goldman Sachs Says

<p><i>Highlights the Board's Critical Skills and Experience Needed to Choose the Company's Next CEO and Drive Future Growth</i></p>
<p><i>Details How H Partners' Disingenuous Attacks on the Company's Strategy and Governance are Putting Shareholder Value at Risk</i></p>
<p><i>Urges Shareholders to Vote <strong>"FOR ALL" </strong>Harley-Davidson Director Nominees on the <strong>WHITE</strong> Proxy Card <strong>TODAY</strong></i></p>
<p>MILWAUKEE, May 5, 2025 /PRNewswire/ -- Harley-Davidson, Inc. (the "Company" or "Harley-Davidson") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) Monday sent a <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420068-1&amp;h=3274074551&amp;u=https%3A%2F%2Fcdn.prod.website-files.com%2F6800145d6ecd04adaedb9964%2F6818eda3b7ee71daa2601879_Harley-Davidson%2520Shareholder%2520Letter%25203.pdf&amp;a=letter+to+shareholders">letter to shareholders</a> in connection with the Company's 2025 Annual Meeting of Shareholders scheduled to be held on May 14, 2025.</p>
<p>The letter highlights:</p>
<ul>
<li>In the face of one of the most challenging operating environments in Harley-Davidson's 120+-year history, the Company has outperformed its peers.</li>
<li>Each of Harley-Davidson's Director nominees is passionate about preserving Harley-Davidson's legacy and committed to supporting a successful leadership transition in line with governance best practices.
<ul>
<li>We believe the Directors targeted by H Partners are critical in choosing the next CEO to lead the Company, as they collectively bring deep institutional knowledge of Harley-Davidson, leadership experience with iconic brands, extensive expertise in manufacturing and engineering and track records of successful business transformation.</li>
</ul>
</li>
<li>After three years with their own representative on the Board – during which time H Partners fully supported the current CEO, endorsed the Hardwire strategic plan and voted in favor of all Directors standing for reelection – H Partners has launched what we view to be a misleading campaign that puts shareholder value and the Company's long-term strategy and thoughtful succession plan all at risk.
<ul>
<li>H Partners' recent U-turn is not about protecting shareholders' interests, it's about getting their own way – seeking to gain control of an American icon after their preferred CEO candidate did not receive even bare majority support.</li>
</ul>
</li>
</ul>


News

Harley-Davidson Defends Strategy, Calls For Shareholder Support Amid H Partners' Criticism

<p><a href="https://openai.com/index/evolving-our-structure/">https://openai.com/index/evolving-our-structure/</a></p>


General

MSFT

NVDA

OpenAI Says Moving To A Normal Capital Structure Where Everyone Has Stock

<p><a href="https://x.com/wolfpackreports/status/1919452350432846210?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/wolfpackreports/status/1919452350432846210?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a></p>


Long Ideas

Trading Ideas

ISRG

Watching Intuitive Surgical; Wolfpack Research Issues Report On The Stock, Stating They Have A Long Position

<p>Oppenheimer  analyst Timothy Horan   initiates coverage on Iridium Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) with a Outperform rating and announces Price Target of $34.</p>


Initiation

IRDM

Oppenheimer Initiates Coverage On Iridium Communications with Outperform Rating, Announces Price Target of $34

<p>Oppenheimer  analyst Timothy Horan   initiates coverage on AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) with a Perform rating.</p>


ASTS

Oppenheimer Initiates Coverage On AST SpaceMobile with Perform Rating

<p><strong>Safehold</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Safehold will report an <strong>earnings per share</strong> (EPS) of $0.42. </p>
<p>The announcement from Safehold is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 7.92% increase in the share price on the subsequent day.</p>
<p>Here's a look at Safehold's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.37</td>
<td>0.37</td>
<td>0.36</td>
<td>0.39</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.37</td>
<td>0.41</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468227_0.png" alt="eps graph" /></p>
<h3>Performance of Safehold Shares</h3>
<p>Shares of Safehold were trading at $16.15 as of May 02. Over the last 52-week period, shares are down 19.67%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analysts' Perspectives on Safehold</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Safehold.</p>
<p>Analysts have given Safehold a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target is $23.67, indicating a potential 46.56% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Outfront Media, Four Corners Property Tr and EPR Props, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Outfront Media, with an average 1-year price target of $19.0, suggesting a potential 17.65% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Four Corners Property Tr, with an average 1-year price target of $30.5, suggesting a potential 88.85% upside.</li>
<li>Analysts currently favor an Neutral trajectory for EPR Props, with an average 1-year price target of $53.2, suggesting a potential 229.41% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Outfront Media, Four Corners Property Tr and EPR Props are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safehold</td>
<td>Neutral</td>
<td>-10.83%</td>
<td>$90.81M</td>
<td>1.12%</td>
</tr>
<tr>
<td>Outfront Media</td>
<td>Neutral</td>
<td>-1.60%</td>
<td>$255.80M</td>
<td>11.33%</td>
</tr>
<tr>
<td>Four Corners Property Tr</td>
<td>Neutral</td>
<td>7.54%</td>
<td>$60.66M</td>
<td>1.82%</td>
</tr>
<tr>
<td>EPR Props</td>
<td>Neutral</td>
<td>2.58%</td>
<td>$148.85M</td>
<td>-0.61%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Safehold ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. Safehold is at the top for Return on Equity.</p>
<h3>All You Need to Know About Safehold</h3>
<p>Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.</p>
<h3>Financial Milestones: Safehold's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Safehold's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-10.83%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Safehold's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>28.34%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Safehold's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.12%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Safehold's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.38%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.8</strong>.</p>
<p><a href="https://www.benzinga.com/quote/SAFE/earnings"><strong>To track all earnings releases for Safehold visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

SAFE

Uncovering Potential: Safehold's Earnings Preview

<p>UFP Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that UFP Techs will report an <strong>earnings per share</strong> (EPS) of $2.01.</p>
<p>The market awaits UFP Techs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.33, which was followed by a 10.46% drop in the share price the next day.</p>
<p>Here's a look at UFP Techs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.13</td>
<td>1.81</td>
<td>1.53</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.46</td>
<td>2.39</td>
<td>1.86</td>
<td>1.66</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-10.0%</td>
<td>4.0%</td>
<td>1.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468216_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of UFP Techs were trading at $202.21 as of May 02. Over the last 52-week period, shares are down 20.7%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/UFPT/earnings"><strong>To track all earnings releases for UFP Techs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


UFPT

An Overview of UFP Techs's Earnings

<p>Great Lakes Dredge &amp; Dock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Great Lakes Dredge &amp; Dock to report an <strong>earnings per share</strong> (EPS) of $0.26.</p>
<p>Anticipation surrounds Great Lakes Dredge &amp; Dock's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.06 in the last quarter, leading to a 5.01% drop in the share price on the following day.</p>
<p>Here's a look at Great Lakes Dredge &amp; Dock's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.23</td>
<td>0.18</td>
<td>0.02</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.29</td>
<td>0.13</td>
<td>0.11</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>7.000000000000001%</td>
<td>0.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468205_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Great Lakes Dredge &amp; Dock were trading at $9.62 as of May 02. Over the last 52-week period, shares are up 9.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GLDD/earnings"><strong>To track all earnings releases for Great Lakes Dredge &amp; Dock visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GLDD

Exploring Great Lakes Dredge & Dock's Earnings Expectations

<p>Madison Square Garden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGE#NYSE">MSGE</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Madison Square Garden will report an <strong>earnings per share</strong> (EPS) of $0.20.</p>
<p>The announcement from Madison Square Garden is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.43, leading to a 2.74% increase in the share price on the subsequent day.</p>
<p>Here's a look at Madison Square Garden's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.99</td>
<td>-0.79</td>
<td>-0.52</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.56</td>
<td>-0.40</td>
<td>-0.53</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-9.0%</td>
<td>5.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468197_0.png" alt="eps graph" /></p>
<h3>Madison Square Garden Share Price Analysis</h3>
<p>Shares of Madison Square Garden were trading at $33.55 as of May 02. Over the last 52-week period, shares are down 14.35%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MSGE/earnings"><strong>To track all earnings releases for Madison Square Garden visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MSGE

What's Next: Madison Square Garden's Earnings Preview

<p>Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Bristow Group to report an <strong>earnings per share</strong> (EPS) of $0.58.</p>
<p>The announcement from Bristow Group is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.49 in the last quarter, leading to a 9.22% increase in the share price on the following day.</p>
<p>Here's a look at Bristow Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.58</td>
<td>0.61</td>
<td>0.56</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.07</td>
<td>0.95</td>
<td>0.96</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>9.0%</td>
<td>9.0%</td>
<td>12.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468187_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Bristow Group were trading at $30.16 as of May 02. Over the last 52-week period, shares are up 4.88%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VTOL/earnings"><strong>To track all earnings releases for Bristow Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VTOL

Insights into Bristow Group's Upcoming Earnings

<p>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Cormedix to report an <strong>earnings per share</strong> (EPS) of $0.23.</p>
<p>The announcement from Cormedix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.08, leading to a 2.45% drop in the share price on the subsequent day.</p>
<p>Here's a look at Cormedix's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.14</td>
<td>-0.10</td>
<td>-0.25</td>
<td>-0.28</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.22</td>
<td>-0.05</td>
<td>-0.25</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468176_0.png" alt="eps graph" /></p>
<h3>Performance of Cormedix Shares</h3>
<p>Shares of Cormedix were trading at $9.38 as of May 02. Over the last 52-week period, shares are up 53.6%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CRMD/earnings"><strong>To track all earnings releases for Cormedix visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CRMD

Earnings Preview For Cormedix

<p>Rayonier Adv Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAM#NYSE">RYAM</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Rayonier Adv Materials to report an <strong>earnings per share</strong> (EPS) of $-0.09.</p>
<p>Rayonier Adv Materials bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 17.62% drop in the share price on the following day.</p>
<p>Here's a look at Rayonier Adv Materials's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.19</td>
<td>-0.08</td>
<td>-0.10</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.10</td>
<td>-0.12</td>
<td>0.19</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>21.0%</td>
<td>30.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468156_0.png" alt="eps graph" /></p>
<h3>Rayonier Adv Materials Share Price Analysis</h3>
<p>Shares of Rayonier Adv Materials were trading at $4.47 as of May 02. Over the last 52-week period, shares are up 8.38%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Rayonier Adv Materials</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Rayonier Adv Materials.</p>
<p>Analysts have provided Rayonier Adv Materials with 1 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $11.0, suggesting a potential 146.09% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Arq, Aspen Aerogels and Alto Ingredients, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Arq, with an average 1-year price target of $9.0, suggesting a potential 101.34% upside.</li>
<li>Analysts currently favor an Buy trajectory for Aspen Aerogels, with an average 1-year price target of $16.8, suggesting a potential 275.84% upside.</li>
<li>Analysts currently favor an Buy trajectory for Alto Ingredients, with an average 1-year price target of $5.5, suggesting a potential 23.04% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Arq, Aspen Aerogels and Alto Ingredients, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayonier Adv Materials</td>
<td>Outperform</td>
<td>0.00%</td>
<td>$36.94M</td>
<td>-2.24%</td>
</tr>
<tr>
<td>Arq</td>
<td>Buy</td>
<td>-3.79%</td>
<td>$9.80M</td>
<td>-0.62%</td>
</tr>
<tr>
<td>Aspen Aerogels</td>
<td>Buy</td>
<td>46.15%</td>
<td>$47.13M</td>
<td>2.02%</td>
</tr>
<tr>
<td>Alto Ingredients</td>
<td>Buy</td>
<td>-13.62%</td>
<td>$-1.39M</td>
<td>-17.19%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Rayonier Adv Materials ranks at the bottom for Revenue Growth with 0.00%, while its peers show negative growth rates. In terms of Gross Profit, Rayonier Adv Materials is at the top with $36.94M. However, its Return on Equity is the lowest at -2.24% compared to positive values for its peers. Overall, Rayonier Adv Materials performs well in Gross Profit but lags behind in Revenue Growth and Return on Equity.</p>
<h3>Unveiling the Story Behind Rayonier Adv Materials</h3>
<p>Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.</p>
<h3>A Deep Dive into Rayonier Adv Materials's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Rayonier Adv Materials displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>0.0%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-3.84%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Rayonier Adv Materials's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.24%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rayonier Adv Materials's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.76%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Rayonier Adv Materials's debt-to-equity ratio surpasses industry norms, standing at <strong>1.02</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/RYAM/earnings"><strong>To track all earnings releases for Rayonier Adv Materials visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RYAM

Exploring Rayonier Adv Materials's Earnings Expectations

<p><strong>Apple, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are trading lower Monday on continued weakness after CEO <strong>Tim Cook</strong> said the company anticipates a $900 million tariff-related hit <a href="https://www.benzinga.com/25/05/45168400/apple-stock-falls-after-cook-warns-of-900m-tariff-impact">in the June quarter.</a></p>
<p><strong>The Details:</strong> Cook said during the company&#8217;s second-quarter earnings call that, "Assuming that the current global tariff rates, policies and applications don't change for the balance of the quarter," Apple expects a $900 million increase in costs.</p>
<p>Cook said the majority of iPhones sold in the US will eventually be made in India, where Apple has already begun shifting production of its most profitable product.</p>
<p>China has long served as the primary manufacturing location for iPhones sold in the U.S. Vietnam is set to become the main production hub for Apple&#8217;s other products, including iPads, Macs, Apple Watches and AirPods sold in the US.</p>
<p>The company&#8217;s supply chain shift follows President <strong>Donald Trump</strong>'s move to impose tariffs of up to 145% on Chinese imports.</p>
<p><strong>What Else:</strong> According to <a href="https://www.bloomberg.com/news/articles/2025-05-05/apple-plans-to-sell-corporate-bonds-in-as-many-as-four-parts?embedded-checkout=true">Bloomberg</a>, Apple is planning to issue investment-grade bonds in up to four parts. The 10-year bonds are expected to price about 0.7 percentage points above Treasuries. </p>
<p>It would be Apple's first bond issuance since 2023.</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/general/entertainment/25/05/45200209/exclusive-netflix-customers-excited-for-original-movies-squid-game-stranger-things-nfl-60-say-this-tops-2025-must-watch-list">EXCLUSIVE: Netflix Customers Excited For Original Movies, &#8216;Squid Game,&#8217; &#8216;Stranger Things,&#8217; NFL: 60% Say This Tops 2025 Must-Watch List</a></strong></p>
<p><strong>AAPL Price Action:</strong> At the time of writing, Apple stock is trading 2.45% lower at $200.31, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a></p>
<p><em>Image: Courtesy of Apple, Inc.</em></p>


AAPL

Apple Stock Slides As Tariff Costs Mount, Bond Sale Planned

<p>Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Camden National to report an <strong>earnings per share</strong> (EPS) of $0.99.</p>
<p>The announcement from Camden National is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.15, leading to a 0.95% increase in the share price the following trading session.</p>
<p>Here's a look at Camden National's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.88</td>
<td>0.83</td>
<td>0.71</td>
<td>0.70</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.03</td>
<td>0.94</td>
<td>0.81</td>
<td>0.86</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>1.0%</td>
<td>1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468147_0.png" alt="eps graph" /></p>
<h3>Market Performance of Camden National's Stock</h3>
<p>Shares of Camden National were trading at $39.59 as of May 02. Over the last 52-week period, shares are up 24.98%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CAC/earnings"><strong>To track all earnings releases for Camden National visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring Camden National's Earnings Expectations

<p>Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Array Technologies to report an <strong>earnings per share</strong> (EPS) of $0.08.</p>
<p>The market awaits Array Technologies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 19.39% drop in the share price the following trading session.</p>
<p>Here's a look at Array Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.17</td>
<td>0.14</td>
<td>0.11</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.16</td>
<td>0.17</td>
<td>0.20</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-19.0%</td>
<td>-3.0%</td>
<td>-21.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468136_0.png" alt="eps graph" /></p>
<h3>Market Performance of Array Technologies's Stock</h3>
<p>Shares of Array Technologies were trading at $5.02 as of May 02. Over the last 52-week period, shares are down 62.36%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ARRY/earnings"><strong>To track all earnings releases for Array Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ARRY

Earnings Outlook For Array Technologies

<p>Oppenheimer  analyst Christopher Glynn   maintains WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) with a Outperform and lowers the price target from $225 to $195.</p>


Oppenheimer Maintains Outperform on WESCO Intl, Lowers Price Target to $195

<p>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Bioventus to report an <strong>earnings per share</strong> (EPS) of $0.02.</p>
<p>Investors in Bioventus are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.07 in the last quarter, leading to a 6.76% drop in the share price on the following day.</p>
<p>Here's a look at Bioventus's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.08</td>
<td>0.03</td>
<td>0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.15</td>
<td>0.06</td>
<td>0.19</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-2.0%</td>
<td>-8.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468117_0.png" alt="eps graph" /></p>
<h3>Performance of Bioventus Shares</h3>
<p>Shares of Bioventus were trading at $7.34 as of May 02. Over the last 52-week period, shares are up 35.94%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Bioventus</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Bioventus.</p>
<p>With 1 analyst ratings, Bioventus has a consensus rating of Buy. The average one-year price target is $15.0, indicating a potential 104.36% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of OrthoPediatrics, RxSight and Sanara MedTech, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for OrthoPediatrics, with an average 1-year price target of $37.83, suggesting a potential 415.4% upside.</li>
<li>Analysts currently favor an Neutral trajectory for RxSight, with an average 1-year price target of $29.0, suggesting a potential 295.1% upside.</li>
<li>Analysts currently favor an Buy trajectory for Sanara MedTech, with an average 1-year price target of $48.5, suggesting a potential 560.76% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for OrthoPediatrics, RxSight and Sanara MedTech are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioventus</td>
<td>Buy</td>
<td>13.45%</td>
<td>$102.66M</td>
<td>-0.11%</td>
</tr>
<tr>
<td>OrthoPediatrics</td>
<td>Buy</td>
<td>40.02%</td>
<td>$35.56M</td>
<td>-4.43%</td>
</tr>
<tr>
<td>RxSight</td>
<td>Neutral</td>
<td>40.71%</td>
<td>$28.79M</td>
<td>-2.13%</td>
</tr>
<tr>
<td>Sanara MedTech</td>
<td>Buy</td>
<td>48.70%</td>
<td>$24.06M</td>
<td>-3.89%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Bioventus ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. Bioventus is at the bottom for Return on Equity.</p>
<h3>Delving into Bioventus's Background</h3>
<p>Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.</p>
<h3>Bioventus's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Bioventus showcased positive performance, achieving a revenue growth rate of <strong>13.45%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Bioventus's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-0.1%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bioventus's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.11%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.02%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.27</strong>, Bioventus faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/BVS/earnings"><strong>To track all earnings releases for Bioventus visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Bioventus's Earnings Outlook

<p><strong>Vivid Seats</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Vivid Seats will report an <strong>earnings per share</strong> (EPS) of $0.07. </p>
<p>Investors in Vivid Seats are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.05, which was followed by a 3.1% drop in the share price the next day.</p>
<p>Here's a look at Vivid Seats's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>0.02</td>
<td>0.07</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.02</td>
<td>0.04</td>
<td>-0.01</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468105_0.png" alt="eps graph" /></p>
<h3>Performance of Vivid Seats Shares</h3>
<p>Shares of Vivid Seats were trading at $2.71 as of May 02. Over the last 52-week period, shares are down 49.17%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Vivid Seats</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Vivid Seats.</p>
<p>With 5 analyst ratings, Vivid Seats has a consensus rating of Buy. The average one-year price target is $4.27, indicating a potential 57.56% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Eventbrite, CuriosityStream and Marcus, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Eventbrite, with an average 1-year price target of $5.83, suggesting a potential 115.13% upside.</li>
<li>Analysts currently favor an Buy trajectory for CuriosityStream, with an average 1-year price target of $3.0, suggesting a potential 10.7% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Marcus, with an average 1-year price target of $26.0, suggesting a potential 859.41% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Eventbrite, CuriosityStream and Marcus, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivid Seats</td>
<td>Buy</td>
<td>0.76%</td>
<td>$147.34M</td>
<td>-0.30%</td>
</tr>
<tr>
<td>Eventbrite</td>
<td>Buy</td>
<td>-12.88%</td>
<td>$52.15M</td>
<td>-4.79%</td>
</tr>
<tr>
<td>CuriosityStream</td>
<td>Buy</td>
<td>-4.34%</td>
<td>$7.36M</td>
<td>-4.69%</td>
</tr>
<tr>
<td>Marcus</td>
<td>Outperform</td>
<td>16.58%</td>
<td>$81.52M</td>
<td>0.21%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Vivid Seats ranks first in revenue growth among its peers. It has the highest gross profit margin. However, it has the lowest return on equity.</p>
<h3>Discovering Vivid Seats: A Closer Look</h3>
<p>Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.</p>
<h3>Vivid Seats's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Vivid Seats's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>0.76%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-0.44%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Vivid Seats's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.3%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vivid Seats's ROA excels beyond industry benchmarks, reaching <strong>-0.05%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Vivid Seats's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.56</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/SEAT/earnings"><strong>To track all earnings releases for Vivid Seats visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SEAT

A Look at Vivid Seats's Upcoming Earnings Report

<p>Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $94.4, a high estimate of $126.00, and a low estimate of $70.00. A 0.63% drop is evident in the current average compared to the previous average price target of $95.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746468083_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Biomarin Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$98.00</td>
<td>-</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$126.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$103.00</td>
<td>$99.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biomarin Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Biomarin Pharmaceutical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Biomarin Pharmaceutical's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Biomarin Pharmaceutical analyst ratings.</strong></a></p>
<h2>Delving into Biomarin Pharmaceutical's Background</h2>
<p>BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.</p>
<h3>Unraveling the Financial Story of Biomarin Pharmaceutical</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Biomarin Pharmaceutical's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-0.29%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Biomarin Pharmaceutical's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>24.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.24%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.63%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average at <strong>0.1</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Smith Douglas Homes

Notizie

Ultime notizie per Smith Douglas Homes (NYSE:SDHC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO